Leuven, Belgium – May 17, 2018 – JSR Life Sciences (JLS) is pleased to announce that it has completed its capacity expansion for production of its Amsphere™ A3 protein-A chromatography resin in Leuven, Belgium. The new facility has been built to the highest quality standards using state of the art engineering and is adjacent to JSR’s existing European operations, JSR Micro NV.
Representing a 3.5X increase in capacity, the facility features a new manufacturing area and lab space. JSR has also added key staff members from the pharma industry to run the increased operations.
JLS’ Amsphere™ A3 has experienced rapid adoption as an alternative option for downstream purification in the biopharmaceutical industry and currently has more than 20 global projects in various stages ranging from Phase I to Phase III.
“Steady demand growth at the global level necessitated our need for expansion,” said Tim Lowery, General Manager for JSR’s Bioprocess Materials. “Having a facility in Europe gives us good diversification and improved ability to supply our growing market share.”
The new facility is undergoing routine testing and auditing and will be ready for commercial manufacturing August 2018.
JSR Life Sciences is a business unit of JSR Corporation providing specialized materials and products to the biotech industry. JSR Life Sciences operates a network of manufacturing facilities, sales offices and R&D labs in key markets throughout North America, Europe and Asia-Pacific. JSR Life Sciences today is focused on diagnostics and research products and downstream bioprocessing materials for pharmaceutical manufacturing.
Contact details
-
Download vCard
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com